Researchers in Germany have identified the culprit behind a previously mysterious neurological disease by pinpointing harmful variants in a gene called CD99L2. The discovery, published in Nature Communications, explains X-linked spastic ataxia and opens new pathways for understanding how certain movement disorders develop at the cellular level.
The breakthrough came from analyzing genetic data on 2,811 patients with various movement disorders including ataxia, hereditary spastic paraplegia, and dystonia. Scientists combined genome-wide genetic analysis with laboratory experiments to show that CD99L2 plays a critical role in how nerve cells communicate with each other, a function that had never been established before.
Until now, CD99L2 was known almost exclusively for its work in the immune system. The gene's involvement in neurological processes was entirely unknown, making its discovery in this context a genuine surprise for the field.
How the protein disruption triggers disease
The CD99L2 protein acts as an activating partner for CAPN1, an enzyme already known to play a role in hereditary spastic paraplegia and ataxia. When disease-causing variants damage the CD99L2 gene, the protein cannot be produced properly, and it cannot interact with CAPN1 as it should.
The result is a cascade of failures. Without adequate CD99L2, CAPN1 activation plummets. This disruption ripples through crucial neuronal signaling pathways, ultimately producing the movement and coordination problems that define spastic ataxia. Laboratory work showed that patients' cells exhibited specific disruptions in synaptic processes, the connections between nerve cells.
"Disease-causing variants lead to disrupted production of the CD99L2 protein in the cell and prevent its interaction with CAPN1," explains Dr. Jonasz Weber, who led the functional studies at Ruhr University Bochum. "Patients' cells also showed specific disruptions of synaptic processes."
The discovery represents a significant win for diagnostic testing. Identifying CD99L2 as a disease-causing gene will allow clinicians to screen patients more effectively and provide families with clearer genetic counseling about inheritance patterns and disease risk.
Equally important, the research demonstrates the power of integrating two different scientific approaches. The genetic data identified which patients had the mutation, but only cellular experiments revealed how that mutation actually damages the nervous system.
"Our results show that genetic diagnostics and functional neuroscience are not mutually exclusive areas," Weber notes. "Only when both disciplines work closely together can a reliable disease mechanism be derived from a genetic variant."
Spastic ataxia is a group of rare neurodegenerative disorders marked by severe problems with movement coordination combined with muscle stiffness and partial paralysis. These symptoms stem from damage to the cerebellum and the motor pathways that control movement. The age of symptom onset and disease progression vary widely depending on which genetic mutation is responsible.
The genetic analysis of the patient cohort was conducted at the University of Tübingen under Dr. Tobias Haack's supervision, while Ruhr University Bochum handled the functional studies of the newly identified gene.
Author Jessica Williams: "This is the kind of methodical detective work that slowly fills in the gaps for rare disease patients who have spent years without answers."
Comments